DOI: 10.1128/CMR.00102-15
Article Information
PubMed
Published By
History
- Published online June 8, 2016.
Copyright & Usage
Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Author Information
- aKU Leuven-University of Leuven, Rega Institute for Medical Research, Department of Microbiology and Immunology, Leuven, Belgium
- bDepartment of Metabolism and Endocrinology, Metabolic Syndrome Research Center, Key Laboratory of Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, The Second Xiangya Hospital, Central South University, Changsha, Hunan, China
- Address correspondence to Erik De Clercq, erik.declercq{at}kuleuven.be, or Guangdi Li, liguangdi.research{at}gmail.com.
Citation De Clercq E, Li G. 2016. Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:695–747. doi:10.1128/CMR.00102-15.
Article usage
- Top
- Article
- SUMMARY
- INTRODUCTION
- OVERVIEW OF NINE HUMAN VIRUSES
- 5-SUBSTITUTED 2′-DEOXYURIDINE ANALOGUES
- NUCLEOSIDE ANALOGUES
- PYROPHOSPHATE ANALOGUES
- NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
- NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS
- PROTEASE INHIBITORS
- INTEGRASE INHIBITORS
- ENTRY INHIBITORS
- ACYCLIC GUANOSINE ANALOGUES
- ACYCLIC NUCLEOSIDE PHOSPHONATE ANALOGUES
- HCV NS5A/NS5B INHIBITORS
- INFLUENZA VIRUS INHIBITORS
- INTERFERONS, IMMUNOSTIMULATORS, OLIGONUCLEOTIDES, AND ANTIMITOTIC INHIBITORS
- FORTHCOMING ANTIVIRAL INHIBITORS
- ANTIVIRAL STRATEGIES AGAINST CURRENT AND EMERGING INFECTIOUS DISEASES
- CONCLUSIONS AND FUTURE PERSPECTIVES
- ACKNOWLEDGMENTS
- FOOTNOTES
- REFERENCES
- Author Bios
- Figures & Data
- Info & Metrics